BioSpace News Archive

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on May 8, 2020 at 10:00 a.m. EDT to report its first quarter 2020 financial results and provide an update on its b

Junshi Biosciences (HKEX: 1877) and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus.

MYOS RENS Technology Inc. (“MYOS” or “the Company”) (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin ® , a proprietary bioactive composition that helps build lean muscle, will announce financial results for the first quarter of 2020 on Friday, May 8, 2020 at 11:30 AM ET .

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer of Bellerophon, will participate in a COVID-19 panel at the upcoming Infectious Disease Virtual Conference presented by Maxim Group on Tuesday, May 5, 2020, at 3:45 PM ET. Bellerophon’s proprietary inhaled nitric oxide (iNO) delivery s

Emmes today announced that Dr. Joe Sliman has been named the company’s chief medical officer (CMO). According to Dr. Anne Lindblad , president and chief operating officer, “The depth and breadth of

DarioHealth Corp. (Nasdaq: DRIO), a leading global digital therapeutics (DTx) innovator, announced today that it has expanded its offering on its chronic care platform application to include behavioral health coaching for stress, anxiety and loneliness, conditions which have recently escalated due to COVID-19 social distancing restriction

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biology solutions provider, owner of Clean Beauty consumer brands and provider of proprietary functional ingredients, today announced that the company will host a conference call for investors and analysts on Friday, May 8, 2020 at 6:00 a.m. PT ( 9:00 a.m. ET ) to discuss its first

Primary PartnerCare quickly modified its proprietary risk algorithm to efficiently deploy clinical resources to its over 20,000 Medicare patients during COVID-19 pandemic

Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that the Company will be releasing financial results for its first quarter ended March 31, 2020, after the closing of the stock market on Thursday, May 7, 2020.

US WorldMeds, LLC announced the launch of GELX® ORAL GEL, a Zinc-Taurine bioactive barrier therapy for the management and relief of oral pain associated with oral mucositis.